Biodefense Market Size & Growth | Industry Forecast 2027

    Biodefense Market to 2027 - Global Analysis and Forecasts by Product (Anthrax, Small Pox, Botulism, Radiation/Nuclear, and Others) and Geography

    Publication Month: Mar 2020 | Report Code: TIPRE00005377 | No. of Pages: 136 | Category: Biotechnology | Status: Published

    The Biodefense market is expected to reach US$ 8,350.74 Mn in 2027 from US$ 4,108.24 Mn in 2019. The market is estimated to grow with a CAGR of 9.4% from 2020-2027.

    Biodefense is referred to the measures taken to restore biosecurity of a group of organism that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care. The growth of the market is attributed to the some key driving factors such as presence of favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM. However, low R&D funding by government in developing and underdeveloped economies are expected to restraint the growth of the biodefense market during the forecast years.

    Lucrative Regional Biodefense Markets


    Lucrative Regional Biodefense Markets

    Get more information on this report :



    Market Insights

    Presence of favorable government initiatives

    Every year, the government is spending heavily on the R&D of vaccines to stay prepared for any bioterrorism attacks. For instance, in 2018, the US government released the National Biodefense Strategy and Implementation Plan, the National Security Strategy, the National Defense Strategy, and the National Counterterrorism Strategy, and the National Counter WMD Strategy, all of which include biosecurity and biodefense. In addition, the US government is also preparing for Global Health Security Strategy and supporting the development of a 2024 framework of the Global Health Security Agenda, which involves prevention, detection, and response to natural, accidental, and intentional biological threats.

    Enhances Influenza Vaccines and Health Security is the Budget which supports the Executive Order 13887, “Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health,” by providing a $95 million increase, compared to the 2020 enacted level, across Health and Human Services (HHS) for influenza vaccine manufacturing infrastructure and innovation; advanced research and development of improved vaccines, therapeutics, and diagnostics; international pandemic preparedness; and improved vaccine coverage nationwide. The Budget also funds HHS biodefense and emergency preparedness procurement through the BioShield program and the Strategic National Stockpile. It includes $175 million to support CDC’s global health security activities, an increase of $50 million compared to the 2020 enacted level.

    As the government engages in these current and future policy activities, understanding the existing biosecurity and biodefense policy, the pharmaceutical companies operating in the biodefense market have considerable opportunities to expand and be prepared for any bioterrorism. For instance, Antibiotic developer Spero Therapeutics has received $15.7 million in federal research funding from Biomedical Advanced Research and Development Authority for its oral carbapenem-class candidate, SPR994, to evaluate the drug’s effectiveness against biological threats, including anthrax, plague and melioidosis. In addition, Biomedical Advanced Research and Development Authority also includes provisions for up to an additional $28.5 million over five years, and will also support Spero’s clinical development of SPR994 in complicated urinary tract infections caused by drug-resistant bacteria. The initiatives of governments worldwide open a window of opportunities for the firms involved in the biodefense sector.

    Product Insights

    The biodefense market, by product, is segmented into anthrax, small pox, botulism, radiation/nuclear and others. In 2019, the anthrax segment accounted for the largest market share in the global biodefense market. The segment is expected to continue its dominance over the forecast period owing to increasing funding by the governments of other countries to develop and stockpile adequate vaccines against anthrax mainly through a variety of initiatives, such as BioShield Act, Biomedical Advanced Research and Development Authority (BARDA), and the Joint Program Executive Office for Chemical & Biological Defense.

    Global Biodefense Market, by Product – 2018 & 2027
    Global Biodefense Market, by Product – 2018 & 2027

    Get more information on this report :



    Strategic Insights

    Product launches, and approvals strategy is commonly adopted by companies to expand their footprint worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in order to expand its product portfolio.

    The market players operating in the biodefense market adopt the strategy of expansion to enlarge customer base across the world, which also permits the players to maintain their brand name globally. For instance, in January 2017, Emergent BioSolutions Inc. has received the German Federal Ministry of Health Approval to market BioThrax (Anthrax Vaccine Adsorbed) manufactured in Building 55 in Germany.

    Global Biodefense Market – By Product

    • Anthrax
    • Small Pox
    • Botulism
    • Radiation/Nuclear
    • Others

    Biodefense Market – By Geography

    • North America

      • US
      • Canada
      • Mexico
    • Europe

      • France
      • Germany
      • Italy
      • UK
      • Spain
      • Rest of Europe
    • Asia Pacific

      • China
      • India
      • South Korea
      • Japan
      • Australia
      • Rest of Asia Pacific
    • Middle East & Africa

      • South Africa
      • Saudi Arabia
      • UAE
      • Rest of Middle East and Africa
    • South America

      • Brazil
      • Argentina
      • Rest of South America

    Company Profiles

    • Bavarian Nordic
    • Alnylam Pharmaceuticals, Inc.
    • SIGA Technologies
    • Emergent BioSolutions Inc.
    • Cleveland Bio Labs
    • Dynavax Technologies
    • Elusys Therapeutics, Inc.
    • Soligenix
    • Altimmune
    • Pluristem Therapeutics

    1. Introduction

    1.1 Scope of the Study

    1.2 The Insight Partners Research Report Guidance

    1.3 Market Segmentation

    1.3.1 Global Biodefense Market – By Product

    1.3.2 Global Biodefense Market – By Geography

    2. Biodefense Market – Key Takeaways

    3. Research Methodology

    3.1 Coverage

    3.2 Secondary Research

    3.3 Primary Research

    4. Biodefense – Market Landscape

    4.1 Overview

    4.2 PEST Analysis

    4.2.1 North America

    4.2.2 Europe

    4.2.3 Asia Pacific

    4.2.4 Middle East & Africa

    4.2.5 South and Central America

    4.3 Expert Opinion

    5. Global Biodefense Market – Industry Dynamics

    5.1 Key Drivers

    5.1.1 Presence of Favourable Government Initiatives

    5.1.2 Increase in the Number of Naturally Occurring Outbreaks

    5.1.3 Increasing Threat of Biological Weapons and Nuclear Armed ICBM

    5.2 Key Market Restraints

    5.2.1 Low R&D Funding by Government in Developing and Underdeveloped Economies

    5.3 Key Market Opportunities

    5.3.1 Increased Adoption of Technologies

    5.4 Future Trends

    5.4.1 Predictive Analytics to Reshape Biodefense Market

    5.5 Impact Analysis

    6. Biodefense Market – Global Analysis

    6.1 Global Biodefense Market Revenue Forecast And Analysis

    6.2 Global Biodefense Market, By Geography - Forecast And Analysis

    6.3 Market Positioning of Key Players

    7. Biodefense Market Analysis – By Product

    7.1 Overview

    7.2 Biodefense Market Revenue Share, by Product (2019 and 2027)

    7.1 Anthrax

    7.1.1 Overview

    7.1.2 Anthrax: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

    7.2 Small pox

    7.2.1 Overview

    7.2.2 Small pox: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

    7.3 Botulism

    7.3.1 Overview

    7.3.2 Botulism: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

    7.4 Radiation/Nuclear

    7.4.1 Overview

    7.4.2 Radiation/Nuclear: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

    7.5 Others

    7.5.1 Overview

    7.5.2 Others: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

    8. Biodefense Market – Geographic Analysis

    8.1.1 Overview

    8.1.2 North America: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.1.3 North America: Biodefense Market, by Product, 2018–2027 (USD Million)

    8.1.4 North America: Biodefense Market, by Country, 2019 & 2027 (%)

    8.1.5 US: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.1.5.1 US: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.1.5.2 US: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.1.6 Canada: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.1.6.1 Canada: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.1.6.2 Canada: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.1.7 Mexico: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.1.7.1 Mexico: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.1.7.2 Mexico: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.2 Europe: Biodefense Market

    8.2.1 Overview

    8.2.2 Europe: Biodefense Market - Revenue and Forecast to 2027 (USD Million)

    8.2.3 Europe: Biodefense Market, by Product, 2018–2027 (USD Million)

    8.2.4 Europe: Biodefense Market, by Country, 2018 & 2027 (%)

    8.2.5 Germany: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.2.5.1 Germany: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.2.5.2 Germany: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.2.6 UK: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.2.6.1 UK: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.2.6.2 UK: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.2.7 France: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.2.7.1 France: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.2.7.2 France: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.2.8 Spain: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.2.8.1 Spain: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.2.8.2 Spain: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.2.9 Italy: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.2.9.1 Italy: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.2.9.2 Italy: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.3 Asia Pacific: Biodefense Market

    8.3.1 Overview

    8.3.2 Asia Pacific: Biodefense Market - Revenue and Forecast to 2027 (USD Million)

    8.3.3 Asia Pacific: Biodefense Market, by Product, 2018–2027 (USD Million)

    8.3.4 Asia Pacific: Biodefense Market, by Country, 2018 & 2027 (%)

    8.3.5 China: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.3.5.1 China: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.3.5.2 China: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.3.6 Japan: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.3.6.1 Japan: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.3.6.2 Japan: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.3.7 India: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.3.7.1 India: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.3.7.2 India: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.3.8 South Korea: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.3.8.1 South Korea: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.3.8.2 South Korea: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.3.9 Australia: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.3.9.1 Australia: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.3.9.2 Australia: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.4 South and Central America: Biodefense Market

    8.4.1 Overview

    8.4.2 South and Central America: Biodefense Market - Revenue and Forecast to 2027 (US$ Million)

    8.4.3 South and Central America: Biodefense Market, by Product, 2018–2027 (USD Million)

    8.4.4 South and Central America: Biodefense Market, by Country, 2018 & 2027 (%)

    8.4.5 Brazil: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.4.5.1 Brazil: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.4.5.2 Brazil: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    8.4.6 Argentina: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.4.6.1 Argentina: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    8.4.6.2 Argentina: Biodefense Market, by Product Type, 2018–2027 (USD Million)

    9. IMPACT OF COVID-19 PANDEMIC ON GLOBAL BIODEFENSE MARKET

    9.1 North America: Impact assessment of COVID-19 Pandemic

    9.2 Europe: Impact assessment of COVID-19 Pandemic

    9.3 Asia-Pacific: Impact assessment of COVID-19 Pandemic

    9.4 MEA: Impact assessment of COVID-19 Pandemic

    9.5 SAM: Impact assessment of COVID-19 Pandemic

    10. Biodefence Market –Industry Landscape

    10.1 Overview

    10.2 Growth Strategies in The Biodefence Market, 2016-2020

    10.3 Inorganic Growth Strategies

    10.3.1 Overview

    10.4 Organic Growth Strategies

    10.4.1 Overview

    11. COMPANY PROFILES

    11.1 Bavarian Nordic

    11.1.1 Key Facts

    11.1.2 Business Description

    11.1.3 Products and Services

    11.1.4 Financial Overview

    11.1.5 SWOT Analysis

    11.1.6 Key Developments

    11.2 Alnylam Pharmaceuticals, Inc.

    11.2.1 Key Facts

    11.2.2 Business Description

    11.2.3 Products and Services

    11.2.4 Financial Overview

    11.2.5 SWOT Analysis

    11.2.6 Key Developments

    11.3 SIGA Technologies

    11.3.1 Key Facts

    11.3.2 Business Description

    11.3.3 Products and Services

    11.3.4 Financial Overview

    11.3.5 SWOT Analysis

    11.3.6 Key Developments

    11.4 Emergent BioSolutions Inc.

    11.4.1 Key Facts

    11.4.2 Business Description

    11.4.3 Products and Services

    11.4.4 Financial Overview

    11.4.5 SWOT Analysis

    11.4.6 Key Developments

    11.5 Cleveland Bio Labs

    11.5.1 Key Facts

    11.5.2 Business Description

    11.5.3 Products and Services

    11.5.4 Financial Overview

    11.5.5 SWOT Analysis

    11.5.6 Key Developments

    11.6 Dynavax Technologies

    11.6.1 Key Facts

    11.6.2 Business Description

    11.6.3 Products and Services

    11.6.4 Financial Overview

    11.6.5 SWOT Analysis

    11.6.6 Key Developments

    11.7 Elusys Therapeutics, Inc.

    11.7.1 Key Facts

    11.7.2 Business Description

    11.7.3 Products and Services

    11.7.4 Financial Overview

    11.7.5 SWOT Analysis

    11.7.6 Key Developments

    11.8 Soligenix

    11.8.1 Key Facts

    11.8.2 Business Description

    11.8.3 Products and Services

    11.8.4 Financial Overview

    11.8.5 SWOT Analysis

    11.8.6 Key Developments

    11.9 Altimmune

    11.9.1 Key Facts

    11.9.2 Business Description

    11.9.3 Products and Services

    11.9.4 Financial Overview

    11.9.5 SWOT Analysis

    11.9.6 Key Developments

    11.10 pluristem

    11.10.1 Key Facts

    11.10.2 Business Description

    11.10.3 Products and Services

    11.10.4 Financial Overview

    11.10.5 SWOT Analysis

    11.10.6 Key Developments

    12. Appendix

    12.1 About The Insight Partners

    12.2 Glossary of Terms


    LIST OF TABLES

    Table 1. North America Biodefense Market, by Product– Revenue and Forecast to 2027 (USD Million)

    Table 2. US Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 3. Canada Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 4. Mexico Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 5. Europe Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 6. Germany Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 7. UK Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 8. France Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 9. Spain Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 10. Itlay Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 11. Asia Pacific Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 12. China Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 13. Japan Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 14. India Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 15. South Korea Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 16. Australia Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 17. South and Central America Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 18. Brazil Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 19. Argentina Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

    Table 20. Recent Inorganic Growth Strategies In The Biodefence Market

    Table 21. Recent Organic Growth Strategies In The Biodefence Market

    Table 22. Glossary of Terms, Skin aesthetic devices market


    LIST OF FIGURES

    Figure 1. Biodefense Market Segmentation

    Figure 2. Biodefense Segmentation, By Region

    Figure 3. Global Biodefense Market Overview

    Figure 4. The Anthrax Segment Held Largest Share Of Product Segment In Biodefense Market

    Figure 5. Asia-Pacific Region Is Expected to Show Remarkable Growth During the Forecast Period

    Figure 6. Global Biodefense Market, By Geography (US$ Million)

    Figure 7. Global Biodefense Market- Leading Country Markets (US$ Million)

    Figure 8. Global Biodefense Market, Industry Landscape

    Figure 9. North America PEST Analysis

    Figure 10. Europe: PEST Analysis

    Figure 11. Asia Pacific PEST Analysis

    Figure 12. Middle East & Africa PEST Analysis

    Figure 13. South and Central America PEST Analysis

    Figure 14. Global Biodefense Market – Revenue Forecast And Analysis – 2019- 2027

    Figure 15. Global Biodefense Market – By Geography Forecast And Analysis – 2019- 2027

    Figure 16. Market Positioning Of Key Players In Global Biodefense Market

    Figure 17. Biodefense Market Revenue Share, by Product (2019 and 2027)

    Figure 18. Anthrax: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 19. Small pox: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 20. Botulism: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 21. Radiation/Nuclear: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 22. Others: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)

    Figure 23. North America: Biodefense Market, by Key Country – Revenue (2019) (USD Million)

    Figure 24. North America Biodefense Market Revenue and Forecast to 2027 (USD Million)

    Figure 25. North America: Biodefense Market, by Country, 2019 & 2027 (%)

    Figure 26. US: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 27. Canada: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 28. Mexico: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 29. Europe: Biodefense Market, by Key Country – Revenue (2019) (USD Million)

    Figure 30. Europe Biodefense Market Revenue and Forecast to 2027 (USD Million)

    Figure 31. Europe: Biodefense Market, by Country, 2018 & 2027 (%)

    Figure 32. Germany: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 33. UK: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 34. France: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 35. Spain: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 36. Italy: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 37. Asia Pacific: Biodefense Market, by Key Country – Revenue (2019) (USD Million)

    Figure 38. Asia Pacific Biodefense Market Revenue and Forecast to 2027 (USD Million)

    Figure 39. China: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 40. Japan: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 41. India: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 42. South Korea: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 43. Australia: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 44. South and Central America: Biodefense Market, by Key Country – Revenue (2019) (USD Million)

    Figure 45. South and Central America Biodefense Market Revenue and Forecast to 2027 (USD Million)

    Figure 46. South and Central America: Biodefense Market, by Country, 2018 & 2027 (%)

    Figure 47. Brazil: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 48. Argentina: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

    Figure 49. IMPACT OF COVID-19 PANDEMIC IN NORTH AMERICAN COUNTRY MARKETS

    Figure 50. IMPACT OF COVID-19 PANDEMIC IN EUROPEAN COUNTRY MARKETS

    Figure 51. IMPACT OF COVID-19 PANDEMIC IN ASIA PACIFICAN COUNTRY MARKETS

    Figure 52. IMPACT OF COVID-19 PANDEMIC IN MIDDLE EAST AND AFRICAN COUNTRY MARKETS

    Figure 53. IMPACT OF COVID-19 PANDEMIC IN SOUTH AND CENRAL COUNTRY MARKETS

    Figure 54. Growth Strategies in the Biodefence Market, 2016-2020

    The List of Companies - Biodefense Market

    1. Bavarian Nordic
    2. Alnylam Pharmaceuticals, Inc.
    3. SIGA Technologies
    4. Emergent BioSolutions Inc.
    5. Cleveland Bio Labs
    6. Dynavax Technologies
    7. Elusys Therapeutics, Inc.
    8. Soligenix
    9. Altimmune
    10. Pluristem Therapeutics
    • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the biodefense market.
    • Highlights key business priorities in order to assist companies to realign their business strategies.
    • The key findings and recommendations highlight crucial progressive industry trends in the global biodefense market, thereby allowing players across the value chain to develop effective long-term strategies.
    • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
    • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
    • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
    TIPRE00005377
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market



    Frequently Asked Questions

    Biodefense is referred to the measures taken to restore biosecurity of a group of organism that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.
    Driving factors such as presence of favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM. Additionally, the future trend such as predictive analytics to reshape biodefense market is likely to increase the growth in the forecast period.
    Global biodefense market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. In North America, the U.S. is the largest market for biodefense. Biological threats occurring to humans, animals and environment are among the most serious issues faced by the US and its national community. As the biological threat continues to increase, the US is focused towards strengthening its capabilities and considering preparation for bio threats and bioterrorism as one of the critical aspects of national security. The federal government in the US coordinates programs, and sets up budgets so as to prevent, respond and take actions against biological disasters.

    Pricing
    • $3000
    • $4550 $3640
    • $6550 $5240
    • $8550 $6840

        GET FREE SAMPLE PDF

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount   Speak to Analyst